|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1-Soy isoflavone intake and treatment-related symptoms among Chinese American and non-Hispanic White breast cancer survivors** | | | | | | | | | | |
|  | **Menopausal symptomsb** | | **Fatigue** | | **Joint problemsc** | | **Hair loss or thinning** | | **Memory loss** | |
|  | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d |
| Isoflavonesa  Overall  No intake  >0 - <6.3 mg/day  ≥6.3 mg/day  P-trend  Non-Hispanic White  No intake  >0 - <6.3 mg/day  ≥6.3 mg/day  P-trend  Chinese American  No intake  >0 - <6.3 mg/day  ≥6.3 mg/day  P-trend | 66/38  74/55  63/69  51/22  38/24  19/19  15/16  36/31  44/55 | Reference  0.50 (0.25, 0.99)  0.48 (0.23, 0.96)  0.05  Reference  0.42 (0.15, 1.19)  0.24 (0.07, 0.78)  0.01  Reference  0.52 (0.17, 1.59)  0.61 (0.21, 1.79)  0.55 | 59/45  71/58  66/66  39/34  30/32  11/27  20/11  41/26  55/39 | Reference  0.62 (0.33, 1.16)  0.43 (0.22, 0.84)  0.01  Reference  0.58 (0.25, 1.37)  0.18 (0.06, 0.52)  0.002  Reference  0.78 (0.26, 2.30)  0.77 (0.27, 2.15)  0.66 | 54/50  67/62  65/67  35/38  27/35  14/24  19/12  40/27  51/43 | Reference  0.80 (0.43, 1.46)  0.56 (0.30, 1.06)  0.07  Reference  0.56 (0.23, 1.34)  0.40 (0.15, 1.06)  0.06  Reference  1.14 (0.42, 3.12)  0.75 (0.28, 1.96)  0.38 | 41/64  57/72  47/84  23/50  24/38  12/26  18/13  33/34  35/58 | Reference  0.90 (0.49, 1.68)  0.65 (0.34, 1.25)  0.19  Reference  1.02 (0.41, 2.51)  0.72 (0.26, 1.96)  0.56  Reference  0.56 (0.20, 1.52)  0.46 (0.17, 1.22)  0.14 | 33/71  42/87  39/93  15/58  15/47  7/31  18/13  27/40  32/62 | Reference  0.77 (0.40, 1.48)  0.58 (0.29, 1.15)  0.12  Reference  1.14 (0.45, 2.88)  0.75 (0.25, 2.25)  0.69  Reference  0.50 (0.17, 1.42)  0.41 (0.15, 1.14)  0.12 |
| aTertiles.  bMenopausal symptoms: Hot flashes or night/cold sweats, vaginal dryness/pain with intercourse, vaginal discharge.  cJoint problems: muscle pain, joint stiffness, joint pain, bone thinning.  dMultivariable logistic regression adjusted for age (continuous), ethnicity (Chinese American, non-Hispanic White), menopausal status (premenopause, treatment induced menopause, perimenopause, postmenopause), BMI (continuous), physical activity (active, minimally active, inactive), endocrine therapy (none, tamoxifen, aromatase inhibitor), time since diagnosis (<24 months, 24-36 months, ≥36 months), and cancer stage (0, I, II, III). | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 2-Glucosinoate intake and treatment-related symptoms among Chinese American and non-Hispanic White breast cancer survivors** | | | | | | | | | | |
|  | **Menopausal symptomsb** | | **Fatigue** | | **Joint problemsc** | | **Hair loss or thinning** | | **Memory loss** | |
|  | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d |
| Glucosinolatesa  Overall  ≤20.4 mg/day  >20.4 - <50.1 mg/day  >50.1 mg/day  P-trend  Non-Hispanic White  ≤20.4 mg/day  >20.4 - <50.1 mg/day  >50.1 mg/day  P-trend  Chinese American  ≤20.41mg/day  >20.4 - <50.1 mg/day  >50.1 mg/day  P-trend | 71/50  69/51  63/61  45/35  35/30  28/20  26/25  34/31  35/41 | Reference  0.80 (0.42, 1.53)  0.57 (0.30, 1.10)  0.10  Reference  1.49 (0.53, 4.13)  0.75 (0.26, 2.17)  0.67  Reference  0.72 (0.27, 1.86)  0.48 (0.18, 1.22)  0.12 | 60/61  68/52  68/56  30/40  29/26  21/27  30/21  39/26  47/29 | Reference  1.11 (0.62, 2.01)  1.14 (0.63, 2.07)  0.65  Reference  1.41 (0.59, 3.35)  0.99 (0.41, 2.40)  0.93  Reference  0.92 (0.37, 2.31)  1.10 (0.44, 2.72)  0.81 | 59/62  61/59  66/58  28/42  24/31  24/24  31/20  37/28  42/34 | Reference  0.90 (0.51, 1.58)  1.13 (0.63, 2.01)  0.69  Reference  0.89 (0.37, 2.13)  1.15 (0.47, 2.76)  0.80  Reference  1.16 (0.50, 2.67)  1.20 (0.51, 2.77)  0.68 | 46/75  55/65  44/79  18/52  23/32  18/30  28/23  32/33  26/49 | Reference  1.11 (0.62, 1.98)  0.74 (0.41, 1.36)  0.37  Reference  2.13 (0.84, 5.39)  1.59 (0.60, 4.21)  0.28  Reference  0.61 (0.26, 1.53)  0.30 (0.12, 0.73)  0.007 | 34/87  39/81  41/83  9/61  13/42  15/33  25/26  26/39  26/50 | Reference  0.98 (0.53, 1.83)  1.09 (0.58, 2.05)  0.77  Reference  1.66 (0.59, 4.69)  3.09 (1.11, 8.63)  0.03  Reference  0.60 (0.25, 1.44)  0.50 (0.20, 1.23)  0.14 |
| aTertiles.  bMenopausal symptoms: Hot flashes or night/cold sweats, vaginal dryness/pain with intercourse, vaginal discharge.  cJoint problems: muscle pain, joint stiffness, joint pain, bone thinning.  dMultivariable logistic regression adjusted for age (continuous), ethnicity (Chinese American, non-Hispanic White), menopausal status (premenopause, treatment induced menopause, perimenopause, postmenopause), BMI (continuous), physical activity (active, minimally active, inactive), endocrine therapy (none, tamoxifen, aromatase inhibitor), time since diagnosis (<24 months, 24-36 months, ≥36 months), and cancer stage (0, I, II, III). | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 3-Cruciferous vegetable and soy intake, endocrine therapy and treatment-related symptoms among Chinese American and non-Hispanic White breast cancer survivors** | | | | | | | | | | |
|  | **Menopausal symptomsb** | | **Fatigue** | | **Joint problemsc** | | **Hair loss or thinning** | | **Memory loss** | |
|  | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d | N  Yes/No | Multivariate OR (95% CI)d |
| Soy Productsa  Non-Users  No intake  >0 - <24.0 g/day  ≥24.0 g/day  P-trend  Tamoxifen  No intake  >0 - <24.0 g/day  ≥24.0 g/day  P-trend  Aromatase Inhibitor  No intake  >0 - <24.0 g/day  ≥24.0 g/day  P-trend  P-interaction5  Cruciferous vegetables1  Non-Users  <33.0 g/day  ≥33.0 - <70.8 g/day  ≥70.8 g/day  P-trend  Tamoxifen  <33.0 g/day  ≥33.0 - <70.8 g/day  ≥70.8 g/day  P-trend  Aromatase Inhibitor  <33.0 g/day  ≥33.0 - <70.8 g/day  ≥70.8 g/day  P-trend  P-interaction5 | 21/21  22/30  16/38  22/5  41/12  33/12  23/12  11/15  14/16  18/30  24/25  17/34  33/9  34/7  29/14  21/10  15/15  12/18 | Reference  0.78 (0.25, 2.41)  0.46 (0.15, 1.35)  0.15  Reference  0.30 (0.05, 1.87)  0.78 (0.12, 4.85)  0.90  Reference  0.22 (0.05, 0.87)  0.66 (0.16, 2.75)  0.43  0.51  Reference  2.04 (0.70, 5.90)  0.86 (0.28, 2.62)  0.75  Reference  1.38 (0.28, 6.63)  0.75 (0.17, 3.34)  0.66  Reference  0.22 (0.05, 0.94)  0.13 (0.02, 0.62)  0.01  0.20 | 25/17  22/30  20/34  12/15  37/16  28/18  22/13  13/13  17/13  20/28  21/28  26/25  22/20  28/13  27/16  18/13  16/14  18/12 | Reference  0.42 (0.14, 1.28)  0.21 (0.06, 0.65)  0.007  Reference  1.53 (0.43, 5.45)  1.26 (0.32, 4.87)  0.81  Reference  0.25 (0.06, 1.07)  0.28 (0.06, 1.27)  0.08  0.39  Reference  1.20 (0.41, 3.48)  1.58 (0.56, 4.43)  0.38  Reference  1.42 (0.45, 4.47)  2.07 (0.62, 6.91)  0.23  Reference  0.58 (0.15, 2.23)  0.48 (0.12, 1.96)  0.30  0.73 | 21/21  26/26  21/33  9/18  28/25  25/21  24/11  14/12  18/12  21/27  24/25  23/28  21/21  19/22  22/21  17/14  18/12  21/9 | Reference  0.51 (0.15, 1.69)  0.31 (0.10, 0.97)  0.05  Reference  1.65 (0.50, 5.48)  1.87 (0.52, 6.73)  0.37  Reference  0.14 (0.02, 0.75)  0.16 (0.03, 0.85)  0.03  0.39  Reference  0.97 (0.31, 3.00)  0.48 (0.15, 1.52)  0.20  Reference  0.63 (0.21, 1.85)  1.02 (0.34, 3.03)  0.90  Reference  0.91 (0.22, 3.64)  0.99 (0.22, 4.43)  0.98  0.41 | 18/24  21/31  16/38  8/19  25/28  20/25  15/20  12/14  10/20  18/30  21/28  16/35  15/27  20/21  18/24  12/19  15/15  10/20 | Reference  0.71 (0.24, 2.10)  0.53 (0.19, 1.49)  0.23  Reference  0.95 (0.26, 3.43)  1.30 (0.33, 5.14)  0.64  Reference  0.69 (0.17, 2.76)  0.36 (0.08, 1.46)  0.16  0.15  Reference  1.25 (0.45, 3.41)  0.37 (0.12, 1.10)  0.08  Reference  1.43 (0.44, 4.65)  1.09 (0.33, 3.59)  0.91  Reference  1.68 (0.41, 6.82)  0.29 (0.06, 1.37)  0.14  0.39 | 14/28  17/35  12/42  5/22  20/33  15/31  14/21  6/20  11/19  11/37  14/35  18/33  9/33  19/22  12/31  10/21  9/21  12/18 | Reference  0.85 (0.27, 2.70)  0.41 (0.12, 1.30)  0.12  Reference  1.97 (0.51, 7.61)  1.25 (0.30, 5.23)  0.98  Reference  0.10 (0.01, 0.60)  0.35 (0.07, 1.57)  0.12  0.89  Reference  1.03 (0.34, 3.16)  0.99 (0.33, 2.95)  0.98  Reference  2.65 (0.78, 8.91)  1.69 (0.48, 5.88)  0.51  Reference  0.31 (0.06, 1.47)  0.41 (0.09, 1.83)  0.27  0.68 |
| aTertiles.  bMenopausal symptoms: Hot flashes or night/cold sweats, vaginal dryness/pain with intercourse, vaginal discharge.  cJoint problems: muscle pain, joint stiffness, joint pain, bone thinning.  dMultivariable logistic regression adjusted for age (continuous), ethnicity (Chinese American, non-Hispanic White), menopausal status (premenopause, treatment induced menopause, perimenopause, postmenopause), BMI (continuous), physical activity (active, minimally active, inactive), endocrine therapy (none, tamoxifen, aromatase inhibitor), time since diagnosis (<24 months, 24-36 months, ≥36 months), and cancer stage (0, I, II, III).  5Logistic regression model additionally including cross-product interaction term for food item and endocrine therapy usage. | | | | | | | | | | |